Protagonist Therapeutics (PTGX): Evaluating Valuation After a 65% Year-to-Date Share Price Surge [Yahoo! Finance]
Protagonist Therapeutics, Inc. (PTGX)
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.protagonist-inc.com
Company Research
Source: Yahoo! Finance
Investors are taking notice of the company's solid revenue and net income growth, which helps fuel ongoing optimism. See our latest analysis for Protagonist Therapeutics. It has been a dynamic year for Protagonist Therapeutics, with the share price rallying impressively and a 65% year-to-date gain turning plenty of heads. Recent momentum reflects both the company's revenue traction and shifting investor confidence, even as the 1-year total shareholder return stands at 46%. With these trends in place, the stock's longer-term outlook feels notably brighter to many onlookers who see continued growth potential. If you are keen to uncover other innovative biotech names on the move, it could be the perfect moment to discover See the full list for free. Yet with shares up so strongly and fundamentals continuing to improve, investors now face an interesting dilemma. Is Protagonist Therapeutics still undervalued, or has the market already priced in all the future growth? Price-to-Ear
Show less
Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTGX alerts
High impacting Protagonist Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTGX
News
- Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.MarketBeat
- Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citizens Jmp from $69.00 to $102.00. They now have a "market outperform" rating on the stock.MarketBeat
PTGX
Earnings
- 11/6/25 - Miss
PTGX
Sec Filings
- 11/24/25 - Form 4
- 11/19/25 - Form 4
- 11/14/25 - Form SCHEDULE
- PTGX's page on the SEC website